Figure 1.
Figure 2.
The diagnostic performance of nomogram models for MVI-positive and M2 grade in HCC
| Model | AUC (95%CI) | Accuracy (%) | Sensitivity (%) | Specificity (%) | PPV | NPV |
|---|---|---|---|---|---|---|
| MVI-positive | 0.855(0.833–0.937) | 84.0 | 88.9 | 81.1 | 74.2 | 92.2 |
| M2 grade | 0.805(0.703–0.908) | 79.0 | 74.2 | 82.0 | 71.9 | 83.7 |
Univariate and multivariate logistic regression analysis for predicting M2 grade
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| Odds ratio (95 % CI) | P-value | Odds ratio (95 % CI) | P-value | |
| Clinical features | ||||
| Age (≥ 58 years) | 1.68 (0.68–4.14) | 0.262 | ||
| Sex (male) | 1.27 (0.35–4.69) | 0.703 | ||
| HBeAg(+) | 0.32 (0.09–1.05) | 0.060 | ||
| AFP lg10 | 1.86 (0.75–4.63) | 0.183 | ||
| PIVKA-II lg10 | 1.09 (0.64–1.88) | 0.745 | ||
| Pathological data | ||||
| Satellite nodule | 0.46 (0.18–1.16) | 0.098 | ||
| MRI findings | ||||
| Tumor Max-D (≥ 4.3cm) | 1.39 (0.56–3.42) | 0.480 | ||
| Tumor Min-D (≥ 3.7cm) | 1.07 (0.44–2.61) | 0.888 | ||
| Max/Min-R (≥ 1.22) | 3.53 (1.38–9.04) | 0.009* | 2.91 (1.07–7.92) | 0.036* |
| Irregular tumor shape | 1.32 (0.52–3.32) | 0.560 | ||
| Non-smooth tumor margin | 3.43 (1.33–8.82) | 0.011* | ||
| Confluent multinodule growth | 3.29 (1.19–9.08) | 0.021* | 3.92 (1.25–12.25) | 0.019* |
| Washin/washout enhanced mode | 0.34 (0.13–0.88) | 0.026* | 0.31 (0.11–0.92) | 0.035* |
| Beak sign | 1.18 (0.48–2.91) | 0.721 | ||
| Arterial Rim-enhancement | 2.15 (0.73–6.34) | 0.167 | ||
| Peritumoral enhancement on AP | 1.99 (0.79–5.01) | 0.143 | ||
| Peritumoral hypointensity on HBP | 1.77 (0.63–4.92) | 0.227 | ||
Univariate and multivariate logistic regression analysis for predicting MVI-positive HCCs
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| Odds ratio (95 % CI) | P-value | Odds ratio (95 % CI) | P-value | |
| Clinical features | ||||
| Age (≥ 57 years) | 1.11 (0.64–1.94) | 0.702 | ||
| Sex (male) | 1.28 (0.60–2.72) | 0.525 | ||
| Etiology (hepatitis B virus) | 1.02 (0.54–1.93) | 0.960 | ||
| AFP (≥ 20ng/mL) | 1.98 (1.12–3.49) | 0.018* | ||
| PIVKA-II lg10 | 1.18 (0.84–1.66) | 0.342 | ||
| Pathological data | ||||
| Edmondson-Steiner (III-IV) | 2.35 (1.05–5.26) | 0.037* | ||
| Satellite nodule | 2.53 (1.43–4.48) | 0.001* | ||
| MRI findings | ||||
| Tumor Max-D (≥ 3.9cm) | 2.14 (1.22–3.77) | 0.008* | ||
| Tumor Min-D (≥ 3.1cm) | 2.04 (1.16–3.59) | 0.014* | ||
| Irregular tumor shape | 4.59 (2.54–8.33) | <0.001* | ||
| Non-smooth tumor margin | 2.93 (1.63–5.27) | <0.001* | ||
| Solitary nodule growth | 0.18 (0.10–0.34) | <0.001* | 0.25 (0.12–0.52) | < 0.001* |
| No/mini enhanced mode | 2.76 (1.31–5.85) | 0.008* | 3.24 (1.19–8.88) | 0.022* |
| Beak sign | 4.07 (2.25–7.38) | <0.001* | ||
| Arterial Rim-enhancement | 2.07 (0.97–4.42) | 0.060 | ||
| Peritumoral enhancement on AP | 5.23 (2.56–10.66) | <0.001* | 5.19 (2.15–12.53) | < 0.001* |
| Peritumoral hypointensity on HBP | 11.26 (5.84–21.68) | <0.001* | 10.74 (5.07–22.75) | < 0.001* |